Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 901–999 of 999

Estrogen replacement therapy for the breast cancer survivor: A reappraisal
DiSaia, P. J. (1997) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199703)64:3 · Cited by 9
Supplementary Health Benefits of Linoleic Acid by Improvement of Vaginal Cornification of Ovariectomized Rats
Parhizkar, S., & Latiff, L. A. (2013) · Europe PMC (PubMed Central) · doi:10.5681/apb.2013.006 · Cited by 9
Sperm Decline—Real or Artifact?
McDonough, P. G., Keiding, N., & Skakkebæk, N. E. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58118-7 · Cited by 9
New potential selective estrogen receptor modulators in traditional Chinese medicine for treating menopausal syndrome
Song, X., Shen, L., Contreras, J. M., Liu, Z., Ma, K., Ma, B., Liu, X., & Wang, D. O. (2024) · Phytotherapy Research · doi:10.1002/ptr.8289 · Cited by 8
“Moreover, MHT is associated with an increased risk for breast cancer after long-term treatment (>10 – 15 years) (Choi et al., 2024; Colditz et al., 1995), as well as blood clot-related conditions such as deep vein thrombosis and pulmonary embolism (Solipuram et al., 2021).”
On informative detection bias in screening studies
Sjölander, A., Humphreys, K., & Palmgren, J. (2007) · Statistics in Medicine · doi:10.1002/sim.3091 · Cited by 8
“[1], Joffe and Colditz [2] and Joffe et al.”
Background
Risk factors of breast cancer in Ramsar and Tonekabon
Keihanian, S., Ghaffari, F., Fotokian, Z., Shoormig, R., & Saravi, M. (2010) · The Journal of Qazvin University of Medical Sciences · Cited by 8
Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer
Landrum, L. M., Zuna, R. E., & Walker, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40067-1.00004-8 · Cited by 8
Amelioration of postmenopausal osteoporosis and anticancer properties of an antioxidant enriched fraction from Hygrophila spinosa T. Anders
Satpathy, S., Patra, A., Hussain, M. D., & Ahirwar, B. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.05.033 · Cited by 8
Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer
Abildgaard, J., Ahlström, M. G., Daugaard, G., Nielsen, D. L., Pedersen, A. T., Lindegaard, B., & Obel, N. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky034 · Cited by 8
“Although observational studies have shown that the use of hormone therapy after natural menopause, regardless of regimen, is associated with an increased risk of breast cancer (15,16), randomized controlled trials have only found progestincontaining HT to be associated with increased risk of breast cancer (17–20), and…”
Background
Melatonin ameliorates the fertilization capacity of oocytes exposed to 17α-ethynylestradiol
Dai, X., Qiu, L., Zhao, B., Gao, Y., Mu, Y., Chu, Z., Du, L., & Xiong, B. (2020) · Reproductive Toxicology · doi:10.1016/j.reprotox.2020.01.004 · Cited by 8
Sphingosylphosphorylcholine blocks ovariectomy‐induced bone loss by suppressing Ca2+/calmodulin‐mediated osteoclast differentiation
Lee, H. Y., Cho, K. M., Kim, M. K., Lee, M., Kim, H., Choi, C. Y., Kim, K. K., Park, J. S., Kim, H., & Bae, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16101 · Cited by 8
Development of a clinical decision rule for triage of women with palpable breast masses
Reeves, M. J., Osuch, J. R., & Pathak, D. R. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00123-9 · Cited by 8
“Definition of independent (predictor) variables Menopausal status was assigned according to previously developed criteria [10].”
Method
Menopausal hormone therapy after breast cancer
Colditz, G. A. (2005) · Breast Cancer Research · doi:10.1186/bcr1272 · Cited by 8
“There is now resounding evidence that use of exogenous hormones by postmenopausal women increases risk for breast cancer [1-3].”
Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study
Lu, J., Zhou, Q., Jiang, Y., Yin, W., & Wang, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102433 · Cited by 9
Whey Protein Concentrate Hydrolysate Prevents Bone Loss in Ovariectomized Rats
Kim, J., Kim, H., Kim, S. H., Imm, J.-Y., & Whang, K. (2015) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3441 · Cited by 8
“However, undesirable side effects have been associated with these treatments, including gastrointestinal upset, nausea, headaches, and breast cancer.(12) Milk is known as a safe food.”
Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis
Suba, Z., & Kásler, M. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29287 · Cited by 8
Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor
Christiansen, L. B., Wenckens, M., Bury, P. S., Gissel, B., Hansen, B. S., Thorpe, S. M., Jacobsen, P., Kanstrup, A., Jørgensen, A. S., Nærum, L., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00679-5 · Cited by 8
Development of a Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry Method for Analysis of Stable 4-Hydroxyequilenin−DNA Adducts in Human Breast Cancer Cells
Wang, Z., Edirisinghe, P. D., Sohn, J., Qin, Z., Geacintov, N. E., Thatcher, G. R. J., & Bolton, J. L. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900063g · Cited by 8
Clinical efficacy of raloxifene in postmenopausal women
Agnusdei, D. (1999) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(98)00280-2 · Cited by 8
Observation and Experiment on the Cusp of Collaboration: A Parallel Examination of Clinical Pharmacology and Pharmacoepidemiology
Lehmann, D. F. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009675 · Cited by 8
“For example, observational studies investigating the association between estrogen exposure and breast cancer have led to results showing at once a lack of an association and a potentially significant causal link.(16,17) As is also the case in clinical pharmacology, such conflicting outcomes can frequently lead to conf…”
Background
Combined Oral Estradiol Valeratenorethisterone Treatment Over Three Years in Postmenopausal Women. 1. Clinical Aspects and Endometrial Histology
Perry, W., Wiseman, R. A., & Cullen, N. M. (1998) · Gynecological Endocrinology · doi:10.3109/09513599809024959 · Cited by 8
Decreased responsiveness of naturally occurring mutants of human estrogen receptor α to estrogens and antiestrogens
Komagata, S., Nakajima, M., Tsuchiya, Y., Katoh, M., Kizu, R., Kyo, S., & Yokoi, T. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.02.006 · Cited by 8
“In addition, estrogens are involved in the growth and development of both uterine and mammary cancers [2,3].”
Background
Osteoporosis in Active Women
Erickson, S. M., Sevier, T. L., & Christie, D. M. (1997) · The Physician and Sportsmedicine · doi:10.3810/psm.1997.11.1439 · Cited by 8
Effets des traitements hormonaux substitutifs de la ménopause sur les facteurs pronostiques des cancers du sein
Bonnier, P., Sakr, R. A., Bessenay, F., Lejeune, C., Charpin, C., Martin, P., & Piana, L. (2000) · Gynécologie Obstétrique & Fertilité · doi:10.1016/s1297-9589(00)00001-1 · Cited by 8
Nonlipid primary and secondary prevention strategies for coronary heart disease
Maron, D. J. (1996) · Clinical Cardiology · doi:10.1002/clc.4960190517 · Cited by 8
Social Constructions of Femaleness in Writing about Cancer
Hanson, B. G. (2001) · Qualitative Health Research · doi:10.1177/104973201129119253 · Cited by 8
“Recent findings indicate that combined estrogen/progesterone therapy, hormone replacement therapy, raises breast cancer risks (Colditz et al., 1995; Vassilopoulou-Sellin, 2000).”
Background
Hormone replacement therapy: part 1 - the evolution of hormone treatment.
Lorentzen, J. (2001) · PubMed · Cited by 8
What's new in preventing and treating osteoporosis?
Andrews, W. C. (1998) · Postgraduate Medicine · doi:10.3810/pgm.1998.10.445 · Cited by 8
Current concepts in secondary prevention after acute myocardial infarction
Mehta, R. H., Bossone, E., & Eagle, K. A. (2000) · Herz · doi:10.1007/bf03044123 · Cited by 8
Hormone Replacement Therapy and Breast Cancer
Bush, T. L., Whiteman, M. K., & Flaws, J. A. (2001) · Obstetrics and Gynecology · doi:10.1097/00006250-200109000-00025 · Cited by 8
Hormonelle Substitutionstherapie und gynäkologische Malignome
Ortmann, O., Diedrich, K., & Schulz, K. ‐. (1997) · Der Gynäkologe · doi:10.1007/pl00003039 · Cited by 8
Chemoprevention with aromatase inhibitors—trial strategies
Goss, P. E., & Strasser, K. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00160-1 · Cited by 8
Patients' perception of risk and breast cancer awareness.
Baum, M. (1997) · British Journal of Radiology · doi:10.1259/bjr.70.836.9486039 · Cited by 8
Hormone replacement therapy: A promoter and modulator of breast cancer
Winchester, D. J. (2004) · Annals of Surgical Oncology · doi:10.1007/bf02524338 · Cited by 8
Hormone replacement therapy and breast cancer: what are the facts?
MacLennan, A. H., & Smith, M. C. (1995) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1995.tb124697.x · Cited by 8
Exposure to pesticides and breast cancer in the city of Petrópolis, Brazil
de Rezende, L. M., Santos, S. D. S., & Monteiro, G. T. R. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-26420-8 · Cited by 7
“74), compared to individuals that used no hormones (Colditz et al. 1995).”
Background
Genistein for glycolipid metabolism in postmenopausal women: a meta-analysis
Yi, X.-Y., Wang, Z.-H., & Wang, Y. (2021) · Climacteric · doi:10.1080/13697137.2020.1859473 · Cited by 7
Estradiol enhances sociosexual behavior and can have proliferative effects in ovariectomized rats
Walf, A. A., & Frye, C. A. (2008) · AGE · doi:10.1007/s11357-008-9079-7 · Cited by 7
“1998) and administration of exogenous E2 to postmenopausal women (Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Magnusson et al. 1999; Colditz et al. 1995).”
Background
Stochastic approach to force field evaluations: conformational analysis of raloxifene, a potential new therapeutic agent for post-menopausal osteoporosis
Boyd, D. B., & Coner, R. (1996) · Journal of Molecular Structure THEOCHEM · doi:10.1016/s0166-1280(96)04587-3 · Cited by 7
Hormonersatztherapie bei internistischen Risikopatientinnen
Mueck, A. O. (2006) · Gyn�kologisch-geburtshilfliche Rundschau · doi:10.1159/000095726 · Cited by 7
HRT, breast and endometrial cancers: strategies and intervention options
Sismondi, P., Biglia, N., Giai, M., Ponzone, R., Roagna, R., Sgrò, L. G., & Campagnoli, C. (1999) · Maturitas · doi:10.1016/s0378-5122(98)00108-x · Cited by 7
“The analysis of single studies provides inconsistent results: risk estimates for women using oestrogens plus progestins reported by American studies do not usually differ from those of women using oestrogen alone [10] [11] [12].”
Result
Efficacy of OST-6, a polyherbal formulation in the management of osteoporosis in postmenopausal women
Ahmed, I., Kumar, L., Circle, A., Kumar, V., Kulkarni, K. S., & Advisor, M. (2002) · Cited by 7
Benefits and Challenges of Hormone Replacement Therapy
Borgelt, L. M., & Umland, E. T. (2000) · Journal of the American Pharmaceutical Association (1961) · doi:10.1016/s0003-0465(15)33223-7 · Cited by 7
Epidemiology of Breast Cancer
Smith, R. A., Brinton, L. A., Kramer, J. L., Jemal, A., & Desantis, C. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5199-2.00002-3 · Cited by 7
Raloxifene
Lewis-Wambi, J. S., & Jordan, V. C. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00294-7 · Cited by 7
Benefits and Challenges of Hormone Replacement Therapy
(2000) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31183-4 · Cited by 7
Cardiovascular Health
Siegler, I. C., Kaplan, B. H., Dras, D. D. V., & Mark, D. B. (1999) · Elsevier eBooks · doi:10.1016/b978-012757230-7/50026-2 · Cited by 7
Hormonal Therapy and Chemoprevention
Bonanni, B., Guerrieri‐Gonzaga, A., Rotmensz, N., Torrisi, R., Pigatto, F., Cazzaniga, M., Mora, S., Diani, S., Robertson, C., & DeCensi, A. (2000) · The Breast Journal · doi:10.1046/j.1524-4741.2000.20064.x · Cited by 7
“A previous analysis from the Nurses’ Health Study (13) showed a moderately elevated risk of breast cancer death among postmenopausal women who were taking oral estrogen or had previously used this therapy for 10 or more years.”
Method
Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use
Johansson, C. M., Anderson, T. J., Bergström, R., Lindgren, A., & Persson, I. (1998) · The Breast · doi:10.1016/s0960-9776(98)90029-7 · Cited by 7
Postmenopausal hormone therapy: the pros and cons
Rivera‐Woll, L., & Davis, S. R. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00555.x · Cited by 7
Épidémiologie des lésions malignes du sein
Espié, M., Tournant, B., Cuvier, C., & Cottu, P. H. (2006) · EMC - Gynécologie · doi:10.1016/s0246-1064(01)00056-1 · Cited by 7
Menopause and hormone replacement: Part 1. Evaluation and treatment
Ratner, S. (2001) · Western Journal of Medicine · doi:10.1136/ewjm.174.6.400 · Cited by 6
HRT and breast cancer risk, what to advise?
von Schoultz, B. (1997) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(96)02636-x · Cited by 7
Hamster estrogen receptor cDNA: cloning and mRNA expression
Bhat, H. K., & Vadgama, J. V. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00026-1 · Cited by 7
Efficacy and tolerability of transdermal 17 beta-estradiol in patients with climacteric symptoms: dose titration according to individual choice
Sefaty, D., & Caulin, F. (1996) · Current Therapeutic Research · doi:10.1016/s0011-393x(96)80060-9 · Cited by 7
Postmenopausal Estrogens and Breast Cancer
Colditz, G. A. (1996) · Journal of the Society for Gynecologic Investigation · doi:10.1016/1071-5576(95)00057-7 · Cited by 7
Estrogen Replacement Therapy in Survivors of Breast Cancer
Eden, J. (1996) · Drugs & Aging · doi:10.2165/00002512-199608020-00006 · Cited by 7
Breast cancer and hormone replacement therapy: putting the risk into perspective
Campagnoli, C., Abbà, C., Ambroggio, S., Biglia, N., & Ponzone, R. (2001) · Gynecological Endocrinology · doi:10.1080/gye.15.s6.53.60 · Cited by 7
Selective oestrogen receptor modulators: a new paradigm for HRT
Baynes, K., & Compston, J. E. (1998) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-199806000-00002 · Cited by 7
Progestins in Hormone Replacement Therapy: Impact on Endometrial and Breast Cancer
Reid, R. L. (2000) · Journal SOGC · doi:10.1016/s0849-5831(16)30494-3 · Cited by 7
Hormone Replacement Therapy in the Gynecologic and Breast Cancer Patient
DiSaia, P. J. (1996) · Cancer Control · doi:10.1177/107327489600300201 · Cited by 7
Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women
Renke, G., Antunes, M., Sakata, R., & Tostes, F. (2024) · Pharmaceuticals · doi:10.3390/ph17091248 · Cited by 6
“It is essential to highlight that these effects of testosterone were not observed in other routes of administration, such as the transdermal route, suggesting that implant therapy appears to promote a more constant release and more stable plasma levels of the hormone [12].”
Background
Hormonal therapies in migraine management: current perspectives on patient selection and risk management
Bentivegna, E., Luciani, M., Scarso, F., Bruscia, C., Chiappino, D., Amore, E., Nalli, G., & Martelletti, P. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.2003706 · Cited by 6
“Regarding the administration method, the risk of ischemic stroke is reduced by transdermal formulations of lower doses of estrogen [59,66].”
Background
The Effect of Mulberry Fruits Extracts on Blood Flow Improvement in Ovariectomized Rats
Choi, K.-H., Shon, J. H., Choi, I.-S., Choi, Y., Bae, S.-J., & Kim, M. (2007) · Journal of Life Science · doi:10.5352/jls.2007.17.4.575 · Cited by 6
V. Amygdalina: Folk Medicine, Analysis, and Potential Application for Cancer Treatment
Izevbigie, E. B., Howard, C., & Lee, K. (2008) · Current Pharmaceutical Analysis · doi:10.2174/157341208783497579 · Cited by 6
Hormone replacement therapy: knowledge, attitudes, and weil-being among middle-aged australian women
France, K., Lee, C., & Schofield, M. J. (1996) · International Journal of Behavioral Medicine · doi:10.1207/s15327558ijbm0303_2 · Cited by 6
Klinische Prüfungen nach der Zulassung
Pigeot, I., & Windeler, J. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1033-6 · Cited by 6
Neuroprotection by Exogenous Estrogenic Compounds Following Traumatic Brain Injury
López-Rodríguez, A. B., Ávila-Rodriguez, M., Vega-Vela, N. E., Capani, F., González, J., García‐Segura, L. M., & Barreto, G. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801479-0.00006-1 · Cited by 6
Mammography in New Hampshire: Characteristics of the Women and the Exams They Receive
Carney, P. A., Goodrich, M., O'Mahony, D. M., Tosteson, A. N. A., Eliassen, M. S., Poplack, S. P., Birnbaum, S. B., Harwood, B. G., Burgess, K. A., Berube, B., et al. (2000) · Journal of Community Health · doi:10.1023/a:1005151914471 · Cited by 6
Evidence-based common sense?
Sherman, M. E. (2008) · PubMed Central · Cited by 6
Women's Health as a Paradigm for Understanding Factors that Mediate Disease
Ness, R. B., & Kuller, L. H. (1997) · Journal of Women s Health · doi:10.1089/jwh.1997.6.329 · Cited by 6
“…studies found, respectively, no increased risk,37 a borderline increased risk,38 and a significantly elevated risk among post-menopausal women.39 A previous meta-analysis estimated that the risk of breast cancer with estrogen therapy was 1.25.40 This controversy probably reflects a…”
Influential
Impact of hormone replacement therapy on the histologic subtype of breast cancer
Zanetti‐Dällenbach, R., Krause, E., Lapaire, O., Gueth, U., Holzgreve, W., & Wight, E. (2008) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-008-0613-8 · Cited by 6
“Combined estrogens–progestin HRT regimens increase breast cancer risk beyond the level associated with estrogens alone [1, 4, 14, 16, 36, 38, 41, 45].”
Background
Menopause and Hormone Replacement Therapy from Holistic and Medical Perspectives
Herrick, C. A., Douglas, V., & Carlson, J. H. (1996) · Issues in Mental Health Nursing · doi:10.3109/01612849609035003 · Cited by 6
Hormonal regulation of the normal breast
von Schoultz, B., Söderqvist, G., Cline, M., Schoultz, E. V., & Skoog, L. K. (1996) · Maturitas · doi:10.1016/0378-5122(96)01007-9 · Cited by 6
Recommendations for hormone therapy in hysterectomized women: importance of new data in clinical management
Faubion, S. S., Kapoor, E., Kuhle, C. L., Sood, R., Thielen, J. M., & Miller, V. M. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.957182 · Cited by 6
“While observational studies have reported a slight increase in breast cancer risk with ET alone after prolonged use [43–46], the risk seems to be higher with the use of EPT regimens containing a synthetic progestogen such as MPA [47].”
Background
Menopause, hormone therapy and breast cancer risk
Vecchia, C. L. (2003) · European Journal of Cancer Prevention · doi:10.1097/00008469-200310000-00015 · Cited by 6
“In the American Nurses’ Health Study cohort (Colditz et al., 1995) the relative risks (RRs) were 1.”
BackgroundInfluential
Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?
Vercambre, M., Fournier, A., Boutron‐Ruault, M., Clavel‐Chapelon, F., Ringa, V., & Berr, C. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm162 · Cited by 7
“epidemiological and clinical studies in the past decade have challenged the concept that HRT has an overall beneficial effect (10-12).”
Background
Tibolone: a tissue-specific approach to the menopause
Palacios, S. (2001) · European Heart Journal Supplements · doi:10.1016/s1520-765x(01)90077-x · Cited by 6
Cancer Prevention, Screening, and Early Detection
Zell, J. A., & Meyskens, F. L. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50030-0 · Cited by 6
Comparison of Breast Cancer Risk Predictive Models and Screening Strategies for Chinese Women
Zhao, Y., Xiong, P., McCullough, L. E., Miller, E. E., Li, H., Huang, Y. C., Zhao, M., Wang, M., Kang, M., Wang, Q., et al. (2017) · Journal of Women s Health · doi:10.1089/jwh.2015.5692 · Cited by 7
“A possible explanation is that our study did not collect data on some previously determined risk factors for women aged 50–65, including exogenous estrogen intake, 35,36 early age at menopause, 37 and multiple abortions.”
Estrogen and progestogen therapy in postmenopausal women
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.002 · Cited by 6
Chemoprevention of Breast Cancer
Fabian, C., & Kimler, B. (2002) · Drugs & Aging · doi:10.2165/00002512-200219010-00004 · Cited by 8
The hormone replacement therapy self‐efficacy scale
Ali, N. S. (1998) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.1998.00744.x · Cited by 6
Hormone Replacement Therapy
Kennard, E. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-246-3_9 · Cited by 6
The Menopause and Hormone Replacement Therapy
Rosevear, S. K. (2002) · doi:10.1002/9780470774397.ch8 · Cited by 6
Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women
Nicolaidou-Politis, V. (1999) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443619965561 · Cited by 6
THE CLINICAL DECISION REGARDING HORMONE REPLACEMENT THERAPY
Johnson, S. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70256-5 · Cited by 6
Effect of SERMs on breast tissue
Goldstein, S. R. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343621 · Cited by 6
Hormone Replacement Therapy and the Risk of Reproductive Cancers
Swan, S. H. (1997) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674829709085583 · Cited by 6
HRT and cancer risk: separating fact from fiction
Schneider, H. P. G. (1999) · Maturitas · doi:10.1016/s0378-5122(99)00065-1 · Cited by 6
“46 [34].”
Method
Hereditary Breast Cancer: Risk Assessment Is the Easy Part
Kelly, P. T. (1999) · The Breast Journal · doi:10.1046/j.1524-4741.1999.005001052.x · Cited by 6
“(30) cite a previous study that found “a 43% increase in death due to breast cancer,” and appear to conclude that the 0.”
Background
Menopausal Hormone Therapy: What We Know Now
Roush, K. M. (2011) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000398539.52283.55 · Cited by 5
Colorectal Cancer
Schaeybroeck, S. V., Lawler, M., Johnston, B. T., Salto‐Tellez, M., Lee, J., Loughlin, P., Wilson, R. H., & Johnston, P. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00077-1 · Cited by 5
Medical Decisions, Estrogen and Aging
Schulkin, J. A. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6686-3 · Cited by 5
Hormone replacement therapy for bone protection in multiparous women: When to initiate it
Cure-Cure, C., & Cure-Ramírez, P. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.111247 · Cited by 5
Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer
Landrum, L. M., Zuna, R. E., & Walker, J. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07419-3.00004-7 · Cited by 5
Association of Microbes with Breast Cancer
Noguti, J., & Lee, D. J. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_7 · Cited by 5
Menopausia: nuevas evidencias, nuevos enigmas
Malacara, J. M. (2003) · Revista de enfermedades infecciosas en pediatría · Cited by 5
Untitled work
Magnusson (1999) · doi:10.1002/(sici)1097-0215(19990505)81:3

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks